Resolutions from Biovitrums AGM

The Biovitrum Annual General Meeting (AGM) convened earlier today  in
Stockholm and  voted in  favour of  all resolutions  proposed at  the
meeting, including:

The AGM approved the proposal  to carry forward the retained  profits
of SEK 388,501,778.

The AGM discharged the  members of the Board  and the President  from
liability for the fiscal year 2008.

The ordinary  Board Members  Håkan  Åström, Wenche  Rolfsen,  Michael
Steinmetz, Hans Wigzell and Mats-Olof Ljungkvist were re-elected  and
Peter Sellei and Hans  Glemstedt were elected  as new board  members.
Håkan Åström was elected Chaiman of the Board.

Anders Hultin  and Toni  Weitzberg have  declined re-election.  Peter
Sellei  is  responsible  for  the  Healthcare  Sector  in  the   Core
Investment Department at Investor AB  and former thoracic surgeon  at
Karolinska Hospital  and  pharma analyst.  Sellei  has an  M.D.  from
Karolinska Institutet.  Hans  Glemstedt  is  a  team  member  in  the
Operating Investment group of Investor  AB and former Senior  Manager
at McKinsey. Glemstedt has a  graduate and MBA from Stockholm  School
of Economics.

The  AGM  approved  the  compensation  to  the  Board  totaling   SEK
2,650,000, of which  SEK 950,000  is paid  to the  Chairman, and  SEK
250,000 is paid to each of the other Board Members. The  compensation
for work in the committees of the Board was approved at SEK 50,000 to
the chairman  of the  Audit Committee  and SEK  25,000 to  the  other
members of  the Audit  Committee  and that  no compensation  will  be
received by the members of  the Remuneration Committee. The AGM  also
approved compensation for  work in  the Scientific  Committee at  SEK
50,000 to the Chairman and SEK 25,000 to each of the other members in
the committee.

The AGM  approved  the  guidelines for  remuneration,  etc.  for  the
Management.

The AGM decided to approve the proposed instructions and charter  for
the Nomination Committee.

The AGM decided to adopt the Board's proposal regarding amendments in
the articles of association in respect of announcement of notice. The
amendment is conditional  upon that the  provisions of the  Companies
Act (SFS  2005:551)  regarding  notice to  general  meeting  will  be
amended.

Furthermore, the AGM  decided to  authorize the Board  to resolve  to
issue new shares.

The AGM approved Biovitrum's  new performance based, long-term  share
program for  2009  ("Share  Program 2009")  comprising  a  resolution
regarding a  directed  issue of  series  C shares  and  a  resolution
regarding authorization for the Board  to repurchase issued series  C
shares. The program  includes up  to 50 managers  and key  employees,
which receive  the  possibility  to be  allocated  common  shares  in
Biovitrum free  of charge.  An offer  to participate  in the  program
shall be provided no later than 31 December 2009. The participants of
the program  are  divided  into  three  categories:  members  of  the
management team and two additional categories for other managers  and
key employees.  For  each  category,  the  board  of  directors  will
determine a maximum value for the  Share Program 2009 related to  the
participant's salary. The  respective maximum  value is,  thereafter,
converted to a maximum number of common shares to be allocated.  With
an assumed share price of SEK  52 for the Biovitrum common share  the
maximum number of common shares  to be allocated amounts to  350,000.
The board of directors resolves on  the number of common shares  that
shall be possible to  receive free of  charge, after nomination  from
the Compensation & Benefits  committee. The program participants  are
nominated based on competence and performance as well as taking  into
consideration the  strategic importance  of retaining  key  employees
within the  business.  The  outcome  of the  Share  Program  2009  is
dependent  on  the  fulfillment   of  targets  for  value   creation,
determined  by  the  board  of  directors,  connected  to  the  total
shareholder return of the Biovitrum common share, during a three year
period as from the date of  the offer to participate in the  program.
The board of directors has  allowed for a preliminary calculation  of
the theoretical value of  the right to  receive allocation of  common
shares in Biovitrum free of charge. Assuming a market price of SEK 52
and based on  probability assessments as  regards the achievement  of
the conditions  as set  out above,  the value  amounts to  SEK  20.70
(39.8% of SEK 52), which can lead to a maximum cost for Share Program
2009 of approximately MSEK 7.3.  Based on the theoretical  assumption
of an annual 10%  increase in the  share price of SEK  52 and on  the
assumption that the  program participants receive  maximum number  of
shares, the  social  security  charges for  Share  Program  2009  are
estimated to amount to approximately MSEK 8.0.

At the statutory meeting  of the Board held  in conjunction with  the
AGM, Mats-Olof Ljungkvist (Chairman),  Peter Sellei and Håkan  Åström
were elected to the Audit  Committee, and Hans Glemstedt  (Chairman),
Håkan Åström  and Michael  Steinmetz to  the Remuneration  Committee.
Michael Steinmetz (Chairman),  Hans Wigzell and  Wenche Rolfsen  were
elected to the Scientific Committee.

For full details on each proposal adopted by the AGM please refer  to
www.biovitrum.com  where  documentation   related  to   the  AGM   is
published.

President and CEO Martin  Nicklasson address to  the meeting will  be
available at www.biovitrum.com.


For more information, contact:
Martin Nicklasson, CEO
Phone: +46 8 697 2545

Göran Arvidson, CFO
Cell phone: +46 8 697 23 27

Erik Kinnman, VP Investor Relations
Cell phone: +46 73 422 15 40
[email protected]

About Biovitrum
Biovitrum is a Swedish pharmaceutical company. The company markets  a
range  of  specialist  pharmaceuticals  internationally.  Using   its
expertise and experience  Biovitrum takes  scientific innovation  all
the way  to the  market and  to specialist  indication patients  with
significant medical  need. Research  expertise and  capabilities  are
focused on development and  production of biotechnology  therapeutics
within our prioritized  areas of hemophilia,  inflammation/autoimmune
diseases and malabsorption. The company has revenues of approximately
SEK 1.2 billion  and around 400  employees. It is  listed on the  OMX
Nordic  Exchange  in   Stockholm.  For  more   information  go  to
www.biovitrum.com.